|
楼主 |
发表于 2008-11-16 22:58:54
|
显示全部楼层
来自: 中国北京
JIMMY 的贴子太有用了,先收藏起来。
最新治疗方案--化疗靶向交叉治疗(2星期化疗,2星期靶向)显著延长无进展生存时间
根据目前在美国芝加哥正在召开的国际肺癌研究协会会议(2008年11月13-11月15) http://www.iaslc.org/报道:
:健择+顺铂/卡铂与特罗凯交叉治疗(2星期化疗,2星期靶向)显著延长无进展生存时间, 这是与会医生介绍:
– In an interesting Asian trial called FASTACT that compared chemo (cisplatin or carboplatin on day 1, and gemcitabine on days 1 and 8 every 28 days) with “intercalated” tarceva (erlotinib) or placebo on days 15-28 (following the practice of pharmacodynamic separation) of each cycle, the patients who received chemo and intercalated tarceva showed a significant improvement in progression free survival. Interestingly, this benefit was seen pretty much across all patient subgroups, including smokers as well as never-smokers, men as well as women, and non-adenocarcinomas as well as adenocarcinomas. There was also a better response rate in the patients who received chemo/erlotinib vs. chemo/placebo, though this didn’t reach statistical significance (the trial only included 154 patients). These results are very interesting, but there was a consensus that these results with Asian patients can’t be generalized to a North American population. It’s also important to bear in mind that the chemo didn’t overlap with tarceva: the treatments alternated, with two weeks of chemo followed by two weeks of tarceva, every 28 days.
在一个有趣亚洲试药中(称为FASTACT),试药比较了化疗(第1天用顺铂或卡铂,第1和8天,用健择,每2 8天一个疗程)交叉特罗凯或安慰剂(疗程的第1 5-28天),而且每个周期完全遵照药效学分离做法。病人得到化疗交叉特罗凯治疗的,显示了显着改善无进展生存率。有趣的是,这种临床受益表现在所有分组,包括吸烟者以及从未吸烟者,男人和妇女,非腺癌以及腺癌。同时,接受化疗/特罗凯组比化疗/安慰剂组,还有更好的反应率,虽然由于人数关系(试药只包括154例),这并没有达到统计学意义。这些结果是非常有趣的。但有一个共识,即这些亚洲患者的结果不能推广到北美人口。有一点是重要的,是要牢记的,化疗与特罗凯没有重叠,是治疗交替,两个星期的化疗之后两个星期的特罗凯,每28天一疗程。 |
|